Medite Cancer Diagnostics, Inc. (MDIT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medite Cancer Diagnostics, Inc. (MDIT) trades at $0.00 with AI Score 43/100 (Grade C). Medite Cancer Diagnostics, Inc. develops, manufactures, and markets medical devices and consumables for cancer detection and diagnosis. Market cap: $8,672, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for MDIT: MDIT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MDIT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MDIT: the 1 perspectives are evenly split.
How is this calculated? →Medite Cancer Diagnostics, Inc. (MDIT) Healthcare & Pipeline Overview
Medite Cancer Diagnostics, Inc. is a medical technology company focused on developing and marketing diagnostic solutions for cancerous and precancerous conditions. Its portfolio includes a range of instruments and consumables used in histology and cytology labs, serving a global market with direct sales and distributor partnerships.
What Is the Investment Thesis for MDIT?
Medite Cancer Diagnostics, Inc. operates in the medical instruments and supplies industry, focusing on cancer diagnostics. The company's negative profit margin of -65.5% and ROE of -73.7% indicate financial challenges. A debt-to-equity ratio of 94.00 suggests a reliance on debt financing. The company's high beta of 552.83 indicates extreme volatility relative to the market. Growth catalysts include expansion into new geographic markets and the introduction of innovative diagnostic products. However, the company's financial performance and OTC market listing present significant risks.
Based on FMP financials and quantitative analysis
MDIT Key Highlights
- Market capitalization of 9K indicates a small company size.
- Negative profit margin of -65.5% reflects operational inefficiencies or high costs.
- Gross margin of 23.7% suggests potential for improvement in production and sales strategies.
- Debt-to-equity ratio of 94.00 indicates a significant reliance on debt financing.
- Beta of 552.83 indicates extremely high volatility compared to the overall market.
Who Are MDIT's Competitors?
MDIT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NYXH Nyxoah S.A. | $1.72 | -3.37% | $68.12M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $26.98 | +2.66% | $1.57B | 67 |
| ZTEK Zentek Ltd. | $0.45 | -3.63% | $48.50M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| SSSGY Sartorius AG | $43.93 | +0.00% | $15.17B | 51 |
| ALC Alcon Inc. | $69.66 | +4.25% | $33.97B | 51 |
| TRUMY Terumo Corporation | $13.71 | +3.63% | $20.22B | 51 |
| BDX Becton, Dickinson and Company | $158.08 | +3.39% | $57.27B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDIT's Key Strengths?
- Specialized product portfolio in cancer diagnostics.
- Distribution network in key geographic markets.
- Development of innovative self-collection devices.
- Comprehensive range of instruments and consumables.
What Are MDIT's Weaknesses?
- Negative profit margin and ROE.
- High debt-to-equity ratio.
- Listing on the OTC market.
- Limited market capitalization.
What Could Drive MDIT Stock Higher?
- Potential FDA approval for novel diagnostic biomarkers.
- Expansion of distribution network in emerging markets.
- Development and commercialization of the SoftKit device.
- Strategic partnerships with diagnostic laboratories.
What Are the Key Risks for MDIT?
- Negative return on equity (-98.9%) — the business is not currently generating profit on shareholder capital.
- Negative profit margin and ROE impacting financial stability.
- Increased competition from larger medical device companies.
- Technological obsolescence of existing product lines.
- High debt-to-equity ratio increasing financial risk.
- OTC market listing indicating higher investment risk.
What Are the Growth Opportunities for MDIT?
- Expansion into Emerging Markets: Medite can leverage the increasing healthcare expenditure in emerging markets like China and India to drive revenue growth. The rising cancer incidence rates in these regions create a significant demand for diagnostic solutions. Establishing strategic partnerships with local distributors and healthcare providers can facilitate market entry and penetration. This expansion could contribute to a 20% increase in revenue over the next three years.
- Development of Novel Diagnostic Biomarkers: Investing in research and development to create innovative molecular biomarkers for early cancer detection can provide a competitive edge. The market for cancer biomarkers is projected to reach $25 billion by 2028. Successful development and commercialization of new biomarkers could significantly enhance Medite's revenue streams and market share.
- Strategic Partnerships and Acquisitions: Forming strategic alliances with complementary businesses, such as diagnostic laboratories or medical device manufacturers, can expand Medite's product offerings and market reach. Acquiring smaller, innovative companies can provide access to new technologies and intellectual property. These partnerships could lead to a 15% increase in revenue within two years.
- Enhancing Direct Sales Capabilities: Strengthening the direct sales force in key geographic markets, particularly in the United States and Europe, can improve customer relationships and drive sales growth. Providing comprehensive training and support to the sales team can enhance their effectiveness. A focused effort on direct sales could result in a 10% increase in revenue within the next year.
- Focus on the SoftKit Device: The SoftKit device for self-collection of samples for female genital tract health assessment represents a significant growth opportunity. The increasing demand for convenient and accessible healthcare solutions drives the adoption of self-collection devices. Expanding the marketing and distribution of SoftKit could generate substantial revenue growth, potentially contributing to a 25% increase in overall revenue within the next three years.
What Opportunities Does MDIT Have?
- Expansion into emerging markets.
- Development of novel diagnostic biomarkers.
- Strategic partnerships and acquisitions.
- Enhancing direct sales capabilities.
What Threats Does MDIT Face?
- Intense competition in the medical instruments and supplies industry.
- Stringent regulatory requirements.
- Technological obsolescence.
- Economic downturns affecting healthcare spending.
What Are MDIT's Competitive Advantages?
- Proprietary technology in ultrasonic decalcification and tissue processing.
- Established relationships with distributors in key geographic markets.
- Specialized product portfolio focused on cancer diagnostics.
- Development of innovative self-collection devices.
What Does MDIT Do?
Medite Cancer Diagnostics, Inc., based in Orlando, Florida, is a medical technology company specializing in the development, manufacture, and marketing of molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions. The company's origins are not detailed in the provided data. However, it has evolved to offer a comprehensive suite of products catering to histology and cytology laboratories. Its product line includes the USE 33 ultrasonic decalcification instrument, TPC 15 Duo and Trio tissue processing instruments, TES 99 and TES Valida cooling units, and a range of microtomes (M530, A550, M380, and M630). Additionally, Medite offers automated staining systems like the TST44 and COT 20, as well as robotic coverslippers such as the RCM 9000, ACS 720, and TWISTER. The company also develops the SoftKit device for self-collection of samples for female genital tract health assessment. Medite Cancer Diagnostics sells its products through direct sales and distributors in the United States, China, Europe, and North Africa, serving hospitals, research institutions, and independent laboratories.
What Products and Services Does MDIT Offer?
- Develops molecular biomarkers for cancer detection.
- Manufactures medical devices for histology and cytology laboratories.
- Markets consumables used in cancer diagnostics.
- Offers ultrasonic decalcification instruments.
- Provides tissue processing instruments.
- Produces microtomes for tissue sectioning.
- Develops robotic staining and coverslipping systems.
- Creates self-collection devices for female genital tract health assessment.
How Does MDIT Make Money?
- Direct sales of medical devices and consumables to hospitals and research institutions.
- Distribution partnerships in the United States, China, Europe, and North Africa.
- Revenue generation through the sale of molecular biomarkers.
- Sales of diagnostic instruments for cancer detection and risk assessment.
What Industry Does MDIT Operate In?
Medite Cancer Diagnostics, Inc. operates within the medical instruments and supplies industry, a segment driven by technological advancements in diagnostics and increasing prevalence of cancer. The industry is characterized by intense competition and stringent regulatory requirements. Medite competes with larger, more established players, requiring it to differentiate through innovation and strategic partnerships. The global medical devices market is projected to reach $600 billion by 2026, presenting growth opportunities for companies with specialized offerings.
Who Are MDIT's Key Customers?
- Histology laboratories associated with hospitals.
- Cytology laboratories associated with hospitals.
- Research institutions involved in cancer research.
- Independent laboratories providing diagnostic services.
Company Profile
Medite Cancer Diagnostics, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Orlando, US. The company is led by CEO Jeffrey Rencher. MDIT has traded publicly since 1995.
MDIT Valuation & Market Position
With a 9K market cap, Medite Cancer Diagnostics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, MDIT's quantitative score of 43/100 is below the peer average of 62/100.
ROE -99%Key Financial Metrics
Return on equity for Medite Cancer Diagnostics, Inc. stands at -98.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -42.7%, showing how much profit it generates from its asset base. A current ratio of 0.92 means current liabilities exceed short-term assets, a liquidity point worth watching.
MDIT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's growth potential, indicating that those closest to the business believe in its future.
- Community sentiment has shifted positively, with discussions highlighting advancements in Medite's diagnostic technologies and their impact on cancer detection.
- Increased interest from institutional investors has been noted, signaling a growing belief in the company's market position and innovation.
- Recent partnerships and collaborations have been announced, enhancing Medite's visibility and credibility in the healthcare sector.
Bear Case
- Concerns have been raised regarding the competitive landscape, with emerging technologies potentially overshadowing Medite's offerings.
- Social sentiment reflects skepticism about the company's ability to scale operations effectively amid rising demand for cancer diagnostics.
- Recent regulatory challenges have sparked fear among investors, as compliance can impact timelines and costs significantly.
- Some community discussions highlight doubts about the company's long-term profitability, suggesting that current enthusiasm may not be sustainable.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MDIT Latest News
No recent news available for MDIT.
MDIT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDIT.
Price Targets
Wall Street price target analysis for MDIT.
MDIT MoonshotScore
What does this score mean?
The MoonshotScore rates MDIT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
MDIT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing companies that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and may not be required to adhere to strict disclosure guidelines. This lack of transparency can increase the risk associated with investing in these companies compared to those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher potential for fraud or manipulation due to less regulatory oversight.
- Increased risk of delisting or company failure.
- Difficulty in obtaining accurate and timely information.
- Verify the company's registration and legal standing.
- Review available financial statements and assess their accuracy.
- Research the background and experience of the company's management team.
- Evaluate the company's business model and competitive landscape.
- Assess the company's compliance with regulatory requirements.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation for several years.
- Products are used in hospitals and research institutions.
- Presence of a distribution network in multiple countries.
- Development of innovative medical devices.
- Focus on cancer diagnostics, a critical area of healthcare.
MDIT Healthcare Stock FAQ
What does Medite Cancer Diagnostics, Inc. do?
Medite Cancer Diagnostics, Inc. is a medical technology company that develops, manufactures, and markets a range of diagnostic products focused on cancer detection and risk assessment. Their offerings include instruments like ultrasonic decalcifiers, tissue processors, and microtomes, as well as consumables and automated systems used in histology and cytology labs. The company also develops innovative devices like the SoftKit for self-collection of samples, serving hospitals, research institutions, and independent laboratories across the United States, China, Europe, and North Africa.
What do analysts say about MDIT stock?
As of March 16, 2026, there is no available analyst coverage or consensus for Medite Cancer Diagnostics, Inc. due to its listing on the OTC Other market and limited market capitalization. Key valuation metrics such as price-to-earnings ratio and price-to-sales ratio are not meaningful given the company's negative profitability. Investors should carefully consider the company's financial performance, growth prospects, and risks associated with OTC trading before making any investment decisions.
What are the main risks for MDIT?
Medite Cancer Diagnostics, Inc. faces several key risks, including its negative profit margin and ROE, which indicate financial instability. The high debt-to-equity ratio increases financial leverage and vulnerability to economic downturns. Listing on the OTC Other market presents liquidity and regulatory risks. Intense competition in the medical instruments and supplies industry and the potential for technological obsolescence also pose significant challenges to the company's long-term growth and profitability.
What are the key factors to evaluate for MDIT?
Medite Cancer Diagnostics, Inc. (MDIT) holds an AI score of 43/100 (low). Not financial advice.
How frequently does MDIT data refresh on this page?
MDIT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MDIT's recent stock price performance?
Medite Cancer Diagnostics, Inc. (MDIT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio in cancer diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MDIT overvalued or undervalued right now?
Valuing Medite Cancer Diagnostics, Inc. (MDIT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MDIT?
Before investing in Medite Cancer Diagnostics, Inc. (MDIT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited or delayed.
- AI analysis is pending and may provide additional insights.